Cancer prevention by alpha enolase vaccination
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $547,719
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $547,718.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$8,491 | |
| Other Administrative Action | $0 | |
| Original award | $556,210 |
About this award
This federal contract award from the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) is for the "CANCER PREVENTION BY ALPHA ENOLASE VACCINATION" project, which is part of the NCI's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" initiative. The $547,718.84 firm fixed price delivery order contract was awarded on September 15, 2016 with a completion date of February 14, 2020. MD Anderson, a component of the University of Texas System, is the prime contractor and has no set-aside designation. This contract supports MD Anderson's cancer research expertise, including preclinical studies evaluating novel treatments, epidemiologic studies of risk factors, and clinical trials testing new therapies, diagnostic tests, or prevention strategies.
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2016.
How much is contract HHSN26100003 worth?
The government has obligated $547,719 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201500018I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award